Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating miRNA markers show promise as new prognosticators for multiple myeloma.
Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri F. Rocci A, et al. Among authors: efebera ya. Leukemia. 2014 Sep;28(9):1922-6. doi: 10.1038/leu.2014.155. Epub 2014 May 12. Leukemia. 2014. PMID: 24813918 Free PMC article. No abstract available.
Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
Stino AM, Bumma N, Smith R, Davalos L, Allen J, Ye JC, Pianko M, Campagnaro E, Fierro C, Awad A, Murdock B, Pietrzak M, Loszanski G, Kline DM, Efebera Y, Elsheikh B. Stino AM, et al. Eur J Neurol. 2024 Mar;31(3):e16164. doi: 10.1111/ene.16164. Epub 2023 Nov 28. Eur J Neurol. 2024. PMID: 38015467 Free PMC article. Clinical Trial.
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study.
Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD Jr, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Lin TS, Richardson PG, Voorhees P. Nooka AK, et al. Future Oncol. 2022 Dec;18(40):4443-4456. doi: 10.2217/fon-2022-0775. Epub 2023 Feb 17. Future Oncol. 2022. PMID: 36799429
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Ocio EM, Efebera YA, Hájek R, Straub J, Maisnar V, Eveillard JR, Karlin L, Mateos MV, Oriol A, Ribrag V, Richardson PG, Norin S, Obermüller J, Bakker NA, Pour L. Ocio EM, et al. Among authors: efebera ya. Haematologica. 2024 Mar 1;109(3):867-876. doi: 10.3324/haematol.2023.283490. Haematologica. 2024. PMID: 37646657 Free PMC article. Clinical Trial.
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA. Benson DM Jr, et al. Blood. 2010 Sep 30;116(13):2286-94. doi: 10.1182/blood-2010-02-271874. Epub 2010 May 11. Blood. 2010. PMID: 20460501 Free PMC article.
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM Jr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Bléry M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS. Benson DM Jr, et al. Blood. 2011 Dec 8;118(24):6387-91. doi: 10.1182/blood-2011-06-360255. Epub 2011 Oct 26. Blood. 2011. PMID: 22031859 Free PMC article.
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA. Dunavin NC, et al. Among authors: efebera ya. Leuk Lymphoma. 2013 Aug;54(8):1658-64. doi: 10.3109/10428194.2012.751528. Epub 2012 Dec 31. Leuk Lymphoma. 2013. PMID: 23194056 Free PMC article.
Characterization of multiple myeloma vesicles by label-free relative quantitation.
Harshman SW, Canella A, Ciarlariello PD, Rocci A, Agarwal K, Smith EM, Talabere T, Efebera YA, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F. Harshman SW, et al. Among authors: efebera ya. Proteomics. 2013 Oct;13(20):3013-29. doi: 10.1002/pmic.201300142. Proteomics. 2013. PMID: 23983189 Free PMC article.
125 results